Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Posted by Brian Himes on Oct 30th, 2026

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating and six have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $20.60.

A number of equities research analysts have issued reports on MSLE shares. Wells Fargo & Company set a $18.00 price target on Satellos Bioscience in a research note on Thursday, July 9th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Satellos Bioscience in a research note on Monday, August 17th. Craig Hallum began coverage on shares of Satellos Bioscience in a research note on Thursday, October 8th. They set a “buy” rating and a $24.00 price objective for the company. Zacks Research downgraded Satellos Bioscience from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th.

Check Out Our Latest Stock Report on MSLE

Institutional Investors Weigh In On Satellos Bioscience

A hedge fund recently raised its position in Satellos Bioscience stock. AWM Investment Company Inc. boosted its position in Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) by 41.9% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 305,000 shares of the company’s stock after purchasing an additional 90,000 shares during the period. AWM Investment Company Inc. owned about 1.46% of Satellos Bioscience worth $2,338,000 as of its most recent filing with the SEC.

Satellos Bioscience Stock Performance

MSLE opened at $6.82 on Friday. The stock’s fifty day simple moving average is $8.35 and its 200 day simple moving average is $8.28. Satellos Bioscience has a 1-year low of $5.30 and a 1-year high of $13.39.

Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.18). As a group, research analysts expect that Satellos Bioscience will post -1.86 earnings per share for the current fiscal year.

Satellos Bioscience Company Profile

(Get Free Report)

Satellos Bioscience Inc is a biotechnology company focused on developing regenerative medicines for muscle-related diseases and disorders. The company’s research centers on muscle satellite cells, a type of stem cell responsible for repairing and regenerating skeletal muscle after injury or disease.

Satellos is developing small-molecule therapies intended to restore or enhance the natural muscle-regeneration process by correcting impaired satellite-cell function. Its lead program, SAT-3247, is being investigated as an orally administered potential treatment for muscle-wasting conditions, including Duchenne muscular dystrophy.

Founded in Canada, Satellos Bioscience conducts research and drug-development activities from its Canadian operations while pursuing treatments intended for patients in international markets.